1089704-94-8Relevant articles and documents
Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-Site amyloid precursor protein cleaving enzyme (Bace1) inhibitors
Dineen, Thomas A.,Weiss, Matthew M.,Williamson, Toni,Acton, Paul,Babu-Khan, Safura,Bartberger, Michael D.,Brown, James,Chen, Kui,Cheng, Yuan,Citron, Martin,Croghan, Michael D.,Dunn, Robert T.,Esmay, Joel,Graceffa, Russell F.,Harried, Scott S.,Hickman, Dean,Hitchcock, Stephen A.,Horne, Daniel B.,Huang, Hongbing,Imbeah-Ampiah, Ronke,Judd, Ted,Kaller, Matthew R.,Kreiman, Charles R.,La, Daniel S.,Li, Vivian,Lopez, Patricia,Louie, Steven,Monenschein, Holger,Nguyen, Thomas T.,Pennington, Lewis D.,San Miguel, Tisha,Sickmier, E. Allen,Vargas, Hugo M.,Wahl, Robert C.,Wen, Paul H.,Whittington, Douglas A.,Wood, Stephen,Xue, Qiufen,Yang, Bryant H.,Patel, Vinod F.,Zhong, Wenge
, p. 9025 - 9044 (2013/01/15)
We have previously shown that hydroxyethylamines can be potent inhibitors of the BACE1 enzyme and that the generation of BACE1 inhibitors with CYP 3A4 inhibitory activities in this scaffold affords compounds (e.g., 1) with sufficient bioavailability and p